Given pounces on new FDASIA provisions for "faster" direct de novo COLON 2 application
This article was originally published in Clinica
Executive Summary
Given Imaging has seized the direct de novo pathway now available under the FDA Safety and Innovation Act (FDASIA) to apply for market approval of its PillCam COLON 2 capsule endoscopy system for visualisation of the lower gastrointestinal tract. The Yoqneam, Israel firm believes that the pathway introduced by the new guidelines (www.clinica.co.uk, 14 September 2012) may expedite the regulatory approval process “by a few months”. The objective of the COLON 2 is to “improve the standard of care for patients who are currently unable to undergo an exam, while minimising potential adverse events, and reducing the risks associated with radiation-based alternative procedures, such as CT colonography or double-contrast barium enema”.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.